Newron Pharmaceuticals (SIX: NWRN)

Last close As at 20/12/2024

CHF8.11

−0.16 (−1.93%)

Market capitalisation

CHF158m

Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease (PD) is sold in Europe, Japan, the United States and other regions. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase III trial programme targeting schizophrenia.

Latest Insights

View More

Sector

Healthcare

Equity Analyst

Arron Aatkar

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Marco Caremi

    Executive VP of Business Development

  • Stefan Weber

    CEO

Further insights

insight

Healthcare

Newron Pharmaceuticals: EKF 2023 QuickView

insight

Healthcare

Deutsches Eigenkapitalforum (EKF) 2022 healthcare

insight

Consumer

Deutsches Eigenkapitalforum (EKF) 2022

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free